[A20-88] Ibrutinib (CLL) - Benefit assessment according to §35a Social Code Book V

Last updated 04.01.2021

Project no.:
A20-88

Commission:
Commission awarded on 01.10.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Adults with previously untreated chronic lymphocytic leukaemia (CLL)

Result of dossier assessment:

Patients in good general health for whom therapy with fludarabine + cyclophosphamide + rituximab is an option: indication of major added benefit. Other research questions: added benefit not proven.

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form